Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00517114
Status:
COMPLETED
Last Update Posted:
2013-10-23
First Post:
2007-08-15
Brief Title:
Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole Pariet in the Treatment of Reflux Laryngitis in Chinese Patients
Sponsor:
Hospital Authority Hong Kong
Organization:
Hospital Authority Hong Kong
Study Overview
Official Title:
Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole Pariet in the Treatment of Reflux Laryngitis in Chinese Patients
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy of rabeprazole pariet versus placebo in treating reflux laryngitis in Chinese patients Patients who attend the voice clinic of Department of ENT Queen Mary hospital with suspected reflux laryngitis will be recruited A questionnaire will be administered by the research assistant of the Department of Medicine and ENT Queen Mary hospital A 12-week course of PPI versus placebo trial will be commenced and patients symptoms and signs will be documented at 6-week and 12-week time The study will finish after a 12-week course of rabeprazole
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HARECCTR0500033 | None | None | None |